On Thursday, Pacira BioSciences received a positive adjustment to its Relative Strength (RS) Rating, from 88 to 91.
Here Are 3 Keys For Successful Stock Investing
IBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the market's biggest winners typically have an RS Rating north of 80 in the early stages of their moves.
While the stock is not near an ideal buy zone right now, see if it is able to form and break out from a proper consolidation.
Pacira BioSciences reported 0% earnings growth last quarter. Sales increased 1%.
Pacira BioSciences holds the No. 25 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
